Aignostics

Aignostics started in 2018 within the walls of Charité Berlin and the Berlin Institute of Health, based on years of research conducted by the pathology department of Charité, TU Berlin and Fraunhofer HHI. Following initial incubation, it spun-out of Charité and BIH in 2020, and is now focusing on pioneering computational pathology for pharmaceutical research, clinical trials and CDx development. Aignostics develops novel algorithms for use in pre-clinical and translational research, on its own data. The focus lies on assessing complex structures and cell types with AI in H&E, IHC and multiplex IF, in combination with clinical, molecular and proteomics data.
Aignostics builds robust IVDR-compliant AI models from multi-lab data, for H&E, IHC and multiplex IF. Aignostics’s team works in close collaboration with pathologists from Charité and other leading institutes, as well as regulatory experts, and can deploy with its own platform
Aignostics can certify AI models deploy them via third-party platforms, or our its platform for use in central labs and partner institutions, incl. Charité Berlin. They are also working on a suite of proprietary complementary diagnostics.

‍